Zobrazeno 1 - 10
of 133
pro vyhledávání: ''
Autor:
Mariaelena Pierobon, Leslie S L Kim, Lance A. Liotta, Maren K Levin, Emanuel F. Petricoin, Elisa Baldelli, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P4-10
Background: ER- HER2+ BC is comprised of a heterogeneous mix of intrinsic BC subtypes which have differential responsiveness to preop HER2-directed therapies combined with chemotherapy. Patients (pts) with ER- HER2+ BC whose disease progressed while
Autor:
Sachin K. Khiste, Mohammad Burhan Uddin, Ronald A. Hill, Sami Nazzal, Zhijun Liu, Xin Gu, Salman B. Hosain, Kartik R. Roy, Yong-Yu Liu
Publikováno v:
Mol Cancer Ther
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to t
Publikováno v:
Cancer Research. 79:P5-11
Background: CDK4/6 inhibition combined with endocrine therapy is now a standard of care for advanced estrogen receptor (ER) positive breast cancer. Predictive genetic landscape and mechanisms of resistance to CDK4/6 inhibitors have not been described
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Lysiane Huber, David Anthony Barda, Youyan Zhang, Sheng-Bin Peng, Xueqian Gong, Junpeng Xiao, Deqi Guo, Jing Wang, Carmen Curtis, Bradley L. Ackermann, Wayne P. Bocchinfuso, Danalyn Manglicmot, Gregory P. Donoho, Paul D. Cornwell, Ryan J. Linder, Chong Si, Lee J. Burns, Michael J. Chalmers, Xi Lin, Denis J. McCann, Henry James Robert, Robert D. Van Horn, Serge Louis Boulet, Melbert-Brian D. Saflor, John Strelow, Lian Zhou
Publikováno v:
Cancer Research. 81:1259-1259
KRAS-G12C is an important oncogenic mutation in patients with NSCLC, CRC, and other cancer types. Currently, there are no FDA-approved KRAS-G12C inhibitors, and those in clinical development have relatively modest activity compared to other approved
Autor:
Dieter Dorsch, Nina Glaser, Eva Sherbetjian, Ulrich Graedler, Andreas Blum, Michael Busch, Nina Linde, Carl Petersson, Christina Esdar, Aaron Ruff
Publikováno v:
Cancer Research. 81:1482-1482
Oncogenic mutations in cKIT in exons 9 and 11 are the main driver of gastrointestinal stromal tumors (GIST). Imatinib is standard of care in 1L in unresectable metastatic or recurrent GIST, yet secondary resistance mutations in exons 13/14 and 17/18
Autor:
Sachchidanand Tiwari, Bozena Korczak, Steve Laumas, Sireesh Appajosyula, Neha Mehrotra, Anees Mohammad, Harpal Singh, Surender Kharbanda
Publikováno v:
Cancer Research. 81:3082-3082
Triple negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and a worse clinical outcome as compared with other breast cancer subtypes. Doxorubicin (DOX) is considered to be one of the most effective agents in the tre
Autor:
Kyu-Tae Kim, Jeejin Im, Min Kyung Choi, Ky-Youb Nam, Jeong-Hyeok Yoon, Inki Kim, Sojung Park, June H-J. Han
Publikováno v:
Cancer Research. 81:1461-1461
Purpose: Development of the potent and selective checkpoint kinase 2 (CHK2) inhibitor to overcome limiting clinical utility of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Experimental Procedure: Preclinical evaluation of PHI-101 for cellular an
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Jean-Claude Souberbielle, Thierry Capiod, Arnaud Mejean, Stéphane Oudard, Nicolas Barry Delongchamps, Edouard Reyes-Gomez, Florence Boutillon, Natascha Pigat, Mélanie Viltard, Virginie Verkarre, Eve M. Lepicard, Vincent Goffin, Sophie Bernichtein, Philippe Camparo, Gérard Friedlander
Publikováno v:
Cancer Research. 77:355-365
Active surveillance has emerged as an alternative to immediate treatment for men with low-risk prostate cancer. Accordingly, identification of environmental factors that facilitate progression to more aggressive stages is critical for disease prevent